A Phase II combination study of ARGX-110 with the standard of care in T-cell lymphoma.

Trial Profile

A Phase II combination study of ARGX-110 with the standard of care in T-cell lymphoma.

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2016

At a glance

  • Drugs ARGX 110 (Primary)
  • Indications T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Oct 2016 New trial record
    • 22 Sep 2016 According to an arGEN-X media release, company plans to initiate this study before the end of the year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top